<SEC-DOCUMENT>0001477932-25-007111.txt : 20250929
<SEC-HEADER>0001477932-25-007111.hdr.sgml : 20250929
<ACCEPTANCE-DATETIME>20250929095907
ACCESSION NUMBER:		0001477932-25-007111
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250929
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250929
DATE AS OF CHANGE:		20250929

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cosmos Health Inc.
		CENTRAL INDEX KEY:			0001474167
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		ORGANIZATION NAME:           	07 Trade & Services
		EIN:				270611758
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41308
		FILM NUMBER:		251352825

	BUSINESS ADDRESS:	
		STREET 1:		5 AGIOU GEORGIOU, PILEA
		CITY:			THESSALONIKI
		STATE:			J3
		ZIP:			55438
		BUSINESS PHONE:		312-536-3102

	MAIL ADDRESS:	
		STREET 1:		5 AGIOU GEORGIOU, PILEA
		CITY:			THESSALONIKI
		STATE:			J3
		ZIP:			55438

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cosmos Holdings Inc.
		DATE OF NAME CHANGE:	20140106

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRIME ESTATES & DEVELOPMENTS INC
		DATE OF NAME CHANGE:	20091008
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cosm_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025" xmlns:cosm="http://cosm.com/20250929"><head><title>cosm_8k.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html"/></head><body style="text-align:justify;font:10pt times new roman"><div style="display:none;text-align:justify;font:10pt times new roman;margin-left:7%;margin-right:7%;" id="XBRLDIV"><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2025-09-29to2025-09-29" id="ixv-314">0001474167</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2025-09-29to2025-09-29" format="ixt:booleanfalse" id="ixv-315">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cosm-20250929.xsd"/></ix:references><ix:resources><xbrli:context id="From2025-09-29to2025-09-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-29</xbrli:startDate><xbrli:endDate>2025-09-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>WASHINGTON, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="From2025-09-29to2025-09-29" id="ixv-335">8-K</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CURRENT REPORT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date of Report (Date of earliest event reported) <strong><span style="text-decoration:underline"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="From2025-09-29to2025-09-29" format="ixt:datemonthdayyearen" id="ixv-336">September 29, 2025</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:50%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:99%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="From2025-09-29to2025-09-29" id="ixv-337">COSMOS HEALTH INC.</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td style="width:99%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="From2025-09-29to2025-09-29" format="ixt-sec:stateprovnameen" id="ixv-338">Nevada</ix:nonNumeric></strong></p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityFileNumber" contextRef="From2025-09-29to2025-09-29" id="ixv-339">000-54436</ix:nonNumeric></strong></p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="From2025-09-29to2025-09-29" id="ixv-340">27-0611758</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(State or other jurisdiction</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of incorporation)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Commission</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">File Number)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(I.R.S. Employer</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Identification No.)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="From2025-09-29to2025-09-29" id="ixv-341">5 Agiou Georgiou</ix:nonNumeric>,&#160;<ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="From2025-09-29to2025-09-29" id="ixv-342">Pilea</ix:nonNumeric>,&#160;<ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="From2025-09-29to2025-09-29" id="ixv-343">Thessaloniki</ix:nonNumeric>,&#160;<ix:nonNumeric name="dei:EntityAddressCountry" contextRef="From2025-09-29to2025-09-29" format="ixt-sec:countrynameen" id="ixv-344">Greece</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="From2025-09-29to2025-09-29" id="ixv-345">55438</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address of principal executive offices)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Zip Code)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Registrant&#8217;s telephone number, including area code&#160;<strong><span style="text-decoration:underline">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="From2025-09-29to2025-09-29" id="ixv-346">312</ix:nonNumeric>)&#160;<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="From2025-09-29to2025-09-29" id="ixv-347">865-0026</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">N/A</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Former name or former address, if changed since last report.)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:34%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Title of Each Class</strong></p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:28%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Trading </strong><strong>Symbol</strong></p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:34%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Name of Each Exchange </strong><strong>On Which Registered</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="From2025-09-29to2025-09-29" id="ixv-348">Common Stock, $.001 par value</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="From2025-09-29to2025-09-29" id="ixv-349">COSM</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="From2025-09-29to2025-09-29" format="ixt-sec:exchnameen" id="ixv-350">Nasdaq</ix:nonNumeric>&#160;Capital Market</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="From2025-09-29to2025-09-29" format="ixt-sec:boolballotbox" id="ixv-351">&#9744;</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="From2025-09-29to2025-09-29" format="ixt-sec:boolballotbox" id="ixv-352">&#9744;</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="From2025-09-29to2025-09-29" format="ixt-sec:boolballotbox" id="ixv-353">&#9744;</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="From2025-09-29to2025-09-29" format="ixt-sec:boolballotbox" id="ixv-354">&#9744;</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b of this chapter).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Emerging growth company&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="From2025-09-29to2025-09-29" format="ixt-sec:boolballotbox" id="ixv-355">&#9744;</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"/></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item 7.01 Regulation FD Disclosure</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 29, 2025, Cosmos Health Inc. (the &#8220;Company&#8221;) made available its Chief Executive Officer's annual letter to shareholders for the year ended December 31, 2024, dated as of&#160;September 29, 2025. The Chief Executive Officer's annual letter contains information that may be of interest to investors. A copy of the Chief Executive Officer's annual letter is attached hereto as Exhibit 99.1 and incorporated herein by reference.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FORWARD-LOOKING STATEMENTS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Certain statements contained herein constitute forward-looking statements as such term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include, but are not limited to, statements relating to the Company's anticipated strategic plans and related outcomes. Forward-looking statements are not guarantees of future performance, and there can be no assurance that the Company will, or will have the ability to, execute on its anticipated strategic plans or will realize the expected outcome of its plans as anticipated or at all. They represent our intentions, plans, expectations and beliefs and are subject to numerous assumptions, risks and uncertainties. Our future results, financial condition and business may differ materially from those expressed in these forward-looking statements. You can identify many of these statements by words such as &#8220;approximates,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;would,&#8221; &#8220;may&#8221; or other similar expressions in the Company's Annual Report on Form 10-K. For a discussion of factors that could materially affect the outcome of our forward-looking statements, see &#8220;Risk Factors&#8221; in Part I, Item 1A, of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024,&#160;Quarterly Reports on Form 10-Q,&#160;Current Reports on&#160;Form 8-K&#160;&#160;and the other documents filed by the Company with the SEC and any amendments thereto, including the information contained in the attached letter. We do not undertake any obligation to release publicly any revisions to our forward-looking statements to reflect events or circumstances occurring after the date of this Current Report on Form 8-K.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of Section 18, nor shall it be deemed incorporated by reference into any filing of the Company or the Operating Partnership under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Item 9.01</strong><strong> </strong><strong>Financial Statements and Exhibits.</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">(d) Exhibits.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:8%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Description</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cosm_ex991.htm">99.1</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cosm_ex991.htm">Chief Executive Officer&#8217;s Letter, dated September 29, 2025.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">104</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2</p></td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SIGNATURES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>COSMOS HEALTH INC.</strong></p></td><td/></tr><tr style="height:15px"><td style="width:50%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:35%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Date: September 29, 2025</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ George Terzis</em></p></td><td/></tr><tr style="height:15px"><td/><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">George Terzis</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td/><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Financial Officer</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cosm_ex991.htm
<DESCRIPTION>CHIEF EXECUTIVE
<TEXT>
<html><head><title>cosm_ex991.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 99.1</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare Powerhouse with $300M Digital Financing Facility, U.S. Manufacturing Expansion, and AI Innovation</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>CHICAGO, IL / GLOBE NEWSWIRE / September 29, 2025 /</strong><strong> Cosmos Health Inc.</strong><strong> ("Cosmos Health" or the &#8220;Company&#8221;)</strong><strong> (NASDAQ:COSM)</strong>, a diversified, vertically integrated global healthcare group, today announced that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company&#8217;s shareholders.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Dear Fellow Shareholders,</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Cosmos Health stands at a defining moment in its journey. Over the past year, we have made decisive progress - refining our strategy, reinforcing our operations, and positioning every business unit to contribute to a common vision of sustainable growth and long-term value creation.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">From our expanding manufacturing footprint in the United States to the global reach of our Sky Premium Life brand, the strengthening of our wholesale operations, the signing of long-term contract manufacturing agreements, and the breakthroughs emerging from our R&amp;D pipeline, every part of our organization has made meaningful progress. At the same time, the launch of our digital treasury strategy underscores our commitment to innovation and resilience in an evolving global landscape.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">These achievements mark the beginning of a new era for Cosmos Health &#8212; one defined by growth, innovation, and resilience. With the continued trust and support of our shareholders, we are building a company not only prepared for the challenges ahead, but also poised to lead in the years to come.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong><u>I. Vision &amp; Ambition</u></strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Cosmos Health is at a turning point in its journey. We have aligned every business unit around a common goal: creating a global healthcare and life sciences platform that integrates pharmaceuticals, nutraceuticals, manufacturing, logistics, research and innovation, and digital finance under one roof.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Our purpose is clear: to make high-quality healthcare accessible worldwide while driving innovation at the intersection of science, technology, and digital finance. This is not simply about growth for its own sake, but about building a company defined by resilience, creativity, and the capacity to lead in rapidly evolving industries.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>A Bold Ambition for the Future</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Looking ahead to 2030, our ambition is to transform Cosmos Health into a global powerhouse. We will achieve this by scaling our branded products, deepening our scientific pipeline, and harnessing AI and blockchain to reshape both the discovery and delivery of healthcare.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Our long-term direction includes, among other priorities:</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Expanding our global reach</strong> across Europe, North America, the Middle East, and Asia.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Scaling branded nutraceuticals and pharmaceuticals</strong> into globally recognized products.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Building a proprietary therapeutics pipeline</strong> with multi-billion-dollar market potential.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Leveraging AI and blockchain</strong> to redefine drug discovery, intellectual property monetization, and corporate treasury management.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Delivering sustained shareholder returns</strong> through financial innovation, operational excellence, and long-term growth.</p> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">At every step, we balance near-term profitability with long-term investment, ensuring that Cosmos Health remains both innovative and sustainable.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Foundations of Strength</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Our strategy is rooted in three core strengths that give Cosmos Health a significant advantage:</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Diversification: </strong>By operating across multiple healthcare segments, from R&amp;D and pharmaceuticals to consumer brands and logistics, we reduce reliance on any single revenue stream.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Vertical Integration: </strong>Ownership of manufacturing, distribution, and branded products gives us control over quality, cost, and scalability.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Innovation-Driven Growth: </strong>From AI-enabled platforms like Cloudscreen to blockchain-enhanced treasury and supply chain systems, we are embedding innovation into every part of the business.</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Building for the Long Term</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">These foundations allow us to pursue ambitious goals while maintaining resilience. With such foundations in place, we believe Cosmos Health is positioned not only to capture emerging market opportunities but also to help shape the future of global healthcare delivery. Just as importantly, we see them as ensuring that we can navigate market volatility, protect shareholder value, and continuously reinvest in areas of highest growth potential, from branded nutraceuticals and pharmaceuticals to digital health and AI-driven discoveries.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong><u>II. Milestones &amp; Achievements</u></strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">The past year has been one of the most pivotal in Cosmos Health&#8217;s history. We achieved progress on multiple fronts - securing transformative financing, expanding manufacturing capabilities across two continents, scaling our flagship nutraceutical brand into new international markets, and strengthening our innovation pipeline with patents, licensing agreements, and AI-driven R&amp;D.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">These milestones are not isolated wins but interconnected achievements that reinforce our strategic vision of building a diversified, resilient, and innovation-driven healthcare ecosystem. Together, they highlight the depth of our progress, the strength of our execution, and the scale of the opportunities that lie ahead.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Harnessing a $300 Million Digital Asset Facility to Power Growth &amp; Innovation</strong></p> <p style="margin:0px">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">In August 2025, we secured a financing facility from a U.S. institutional investor in the maximum aggregate principal amount of $300 million in the form of senior secured convertible promissory notes. Under the terms of the notes:</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; 72.5% of net proceeds from the sale of each note will be directed toward building a digital treasury reserve, including Ethereum (ETH), Bitcoin (BTC), Solana (SOL) and other digital assets.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; The balance will be allocated to working capital and to accelerating growth initiatives, both organic and through acquisitions.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Implementation is already underway, with ETH purchases commenced under the program, marking the beginning of what we believe will become a powerful new financial lever for the company. The Company doesn&#8217;t view digital-asset treasury reserve as a speculative side venture; it is central to our broader vision.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">With <strong>capacity to invest over $200 million in digital assets</strong>, Cosmos Health is creating one of the largest corporate digital treasury reserves while also retaining significant capital for its core operations. We believe this strategy:</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; Provides exposure to the upside of global digital asset adoption, increasingly embraced by governments and institutions.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; Strengthens our ability to deploy capital across our various business segments.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; Acts both as a diversification tool and a catalyst for growth.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Equally important, this approach positions us to explore blockchain&#8217;s practical applications in healthcare and wellness, creating opportunities to generate value well beyond the balance sheet. By combining financial innovation with operational execution, Cosmos Health is taking a forward-looking approach that reflects the future of both healthcare and technology.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">The scale of this facility is substantial for a company of our size. We are grateful for the confidence shown by our lead investor and proud to have structured a transaction of this magnitude. Our focus now is on maximizing its impact, through disciplined treasury management and by channelling our resources into the continued growth of our Company&#8217;s core healthcare businesses.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Manufacturing Excellence Through Cana Laboratories</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Since acquiring Cana in 2023, we have advanced a multi-million-dollar expansion to modernize its wholly owned 54,000-square-foot facility in Athens, Greece, completing Phase I upgrades in 2024. We believe these investments position Cana to generate more than $10 million in recurring annual gross profit at full capacity.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">What makes Cana&#8217;s transformation particularly compelling is the visibility of its long-term contract pipeline consisting of the following:</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pharmex:</strong> Five-year agreement for 1.5 million bottles of Ambitasol 1L.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Provident Pharmaceuticals:</strong> Order book of 5.02 million units (DE3-SOLE, MIOREL, CALCIFOLIN, DEXA-DOSE, etc.), plus a landmark 10-year contract for 8 million packs across four additional products (Miorelique&#174;, BE Union F.C., and Certorun variations).</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Humacology:</strong> Agreement to manufacture up to 500,000 CBD units.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Medical Pharmaquality:</strong> Agreement for 3 million MYCOFAGYL&#174; pessaries annually.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">With capacity still significantly underutilized, and the potential to further expand output through Phase II upgrades, we believe Cana is positioned to become a cornerstone of our focus on high-margin segments, underpinning long-term growth and driving sustained profitability.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Expanding Manufacturing Across the Atlantic </strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Our global manufacturing footprint expanded further with the establishment of U.S.-based GMP-certified production in 2025 through our partnership with NOOR Collagen. This dual-hub structure in Europe and the United States reduces cross-border complexities, mitigates tariff exposure, and strengthens supply chain resilience.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Specifically, domestic U.S. manufacturing enables us to:</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Capture higher margins</strong> and reduce shipping costs.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Accelerate time-to-market</strong> for new formulations.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Strengthen our positioning with retailers and e-commerce platforms</strong>, where &#8220;Made in USA&#8221; carries strong trust and regulatory credibility.</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Global Expansion of Sky Premium Life&#174;</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Sky Premium Life, our flagship nutraceutical brand, has become central to our global growth strategy. In 2025, we <strong>added more than sixty new formulations, bringing the portfolio to over 150 premium products</strong>. The brand continues to expand internationally, demonstrating rapid acceptance and strong repeat demand across multiple regions. <strong>Additional formulations are already in the pipeline for 2026</strong>, driven by our leading R&amp;D department, ensuring continued innovation and portfolio expansion in the years ahead.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Recent highlights include:</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>United States:</strong> Official launch of U.S. operations entering the $164 billion American nutraceuticals market. Production began with NOOR Collagen, which is expected to generate over $12 million in annualized revenue at approximately 75% gross margins.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>UAE:</strong> Exclusive distribution agreement with Pharmalink. The initial order of 130,000 units was followed by a repeat order of 80,000 units. Projections exceed 3 million units over five years.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Oman:</strong> Agreement signed with Scientific Pharmacy; initial order of 42,000 units supports broader GCC expansion.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Qatar:</strong> Exclusive distribution rights secured with multiple partners, including an initial order of $578,460 covering 35 SKUs.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Central Europe (Slovakia, Hungary, Poland, Czechia):</strong> Distribution agreement with ZENDON s.r.o. provides access to over 6,000 retail and pharmacy stores across the region, including major chains such as Dr. Max, Rossmann, and Teta Drogerie.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Cyprus:</strong> Distribution rollout through Holland &amp; Barrett and local pharmacies via Papaellinas Group, with repeat orders already secured.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Malta:</strong> Sales through Holland &amp; Barrett stores, expanding Cosmos Health&#8217;s retail presence in the Mediterranean region.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Albania:</strong> Entry via partnership with Pharma Cell, delivering an initial $300,000 order.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Sales are also growing through leading <strong>e-commerce platforms,</strong> including Amazon in <strong>Germany, Austria, Spain, France, and the United Kingdom,</strong> providing direct access to consumers across Europe and further reinforcing Sky Premium Life&#8217;s digital reach.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Together, these achievements underscore Sky Premium Life&#8217;s transformation from a regional offering into a truly global brand, trusted by consumers and partners alike in North America, the Middle East, Central Europe, and beyond.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Record Performance at CosmoFarm Wholesale Business</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">CosmoFarm, our wholesale and logistics arm, continues to deliver record-breaking results.&nbsp; In the first ten months of 2024, <strong>CosmoFarm achieved record revenue</strong> of approximately $43 million, an 8.62% increase over the same period in 2023. Gross profit rose by 21%, reflecting both higher volumes and improved margins. Based on the pace of growth, CosmoFarm is projected to <strong>surpass $50 million in annualized revenue.</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Serving over 1,500 pharmacies, it has proven both resilient and scalable, with its wholly owned 29,000-square-foot facility in Athens serving as the operational hub. Investments in automation, procurement, and inventory systems have further boosted efficiency and profitability.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">This strong performance has been driven by:</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Automation upgrades:</strong> Robotic systems including ROWA and SCHAEFER&#8217;s A-frame, improving order accuracy and fulfilment speed.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Operational enhancements:</strong> Better inventory management and procurement processes.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Commercial expansion:</strong> A broadened sales and marketing footprint that continues to strengthen customer relationships.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Bolt-on acquisitions:</strong> Integration of smaller distribution networks, expanding reach and operational scale.&nbsp; </p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Together, we believe that these advancements have reinforced CosmoFarm&#8217;s position as an anchor of stability for Cosmos Health &#8212; providing steady revenues, operational resilience, and a scalable platform for further growth across economic cycles.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>R&amp;D, Patents, and AI Innovation</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Innovation remains at the core of Cosmos Health, and over 2024&#8211;2025 our R&amp;D efforts have made meaningful progress. We have advanced our proprietary obesity treatment, CCX0722, beyond laboratory development and into the clinical trial preparation stage, with a potential launch as early as 2026. Designed with patient safety and tolerability in mind, CCX0722 represents one of our most promising opportunities in a global market of growing importance.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">At the same time, we have expanded our pipeline and intellectual property across multiple therapeutic areas, including autoimmune diseases, neurology, oncology, and allergies. Many of these advances are powered by Cloudscreen, our AI-enabled drug repurposing platform, which combines advanced computational methods with experimental validation to accelerate discovery. This approach has already generated promising candidates in multiple sclerosis, inflammatory disorders, and allergy therapies.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Key achievements include:</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Obesity &amp; Metabolic Disorders:</strong> Advanced CCX0722 toward clinical evaluation, positioning for entry into the global weight-management market.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Oncology:</strong> Acquired full rights to a WIPO-filed CNS cancer patent; filed new AI-driven patents in gliomas and hematologic malignancies with Cloudpharm and the National Hellenic Research Foundation; and secured exclusive worldwide licenses for two patented anticancer therapies targeting <strong>prostate, ovarian, and colorectal cancers</strong>.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Autoimmune &amp; Neurological Disorders:</strong> Expanded pipeline with Cloudscreen-derived candidates for <strong>multiple sclerosis</strong> and <strong>inflammatory conditions</strong>.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Allergy Treatments:</strong> Initiated preclinical programs on novel<strong> allergy therapies</strong>.</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Together, these initiatives reflect our dual focus: developing proprietary products with global potential while leveraging scientific innovation to enhance the profitability and differentiation of our portfolio. Every new patent, clinical milestone, and Cloudscreen breakthrough strengthens Cosmos Health&#8217;s long-term growth profile and underscores our commitment to advancing science for the benefit of patients and shareholders.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Portfolio Strengthening</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">We believe our portfolio today is broader and stronger than ever. Alongside our flagship Sky Premium Life brand, we have built complementary pillars in wellness and family health through <strong>Mediterranation&#174;</strong>, inspired by the Mediterranean diet, and <strong>bio-bebe&#174;</strong>, a trusted name in infant nutrition.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">In 2024, we expanded further into pharmaceuticals with the <strong>acquisition of a 10-drug generics portfolio</strong>, giving Cosmos Health direct exposure to the $400 billion global generics market. This diversification strengthens our positioning across multiple healthcare segments, from premium nutraceuticals to essential medicines, and provides a stable platform for sustainable, long-term growth.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">We have also extended our presence into diagnostics through our collaboration with Virax Biolabs, which now spans <strong>Mpox RT-PCR kits</strong> (with rights across Greece, Cyprus, Europe, and the GCC region) and <strong>Avian Influenza Virus PCR kits</strong> (exclusive rights in Greece and Cyprus). These partnerships broaden our exposure to infectious disease testing and reinforce our entry into adjacent high-value markets.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">In addition, Cosmos is advancing its proprietary hygiene brands, <strong>C-Sept&#174;</strong> and <strong>C-Scrub&#174;</strong>, which are gaining momentum in both consumer and institutional channels:</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>United Kingdom:</strong> Actively pursuing a potential<strong> </strong>supply<strong> contract with the UK National Health Service (NHS)</strong>.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Germany:</strong> Sales already underway through established distribution partners.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Together, these developments highlight how Cosmos Health is building a diversified, future-ready healthcare group capable of addressing global demand across consumer products, pharmaceuticals, diagnostics, and hygiene solutions.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Insider Purchases</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">As both CEO and a long-term shareholder, I want to emphasize my personal commitment. Since the inception of Cosmos Health, I have invested more than $18 million of my own capital into the Company, and I now hold over&nbsp;6 million shares.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">I have continued to make consistent share purchases, including in multiple recent rounds, demonstrating my unwavering conviction in the value we are building together. These are not symbolic gestures but a purposeful long-term commitment which reflects my belief in our strategy, our people, and our future. My interests remain fully aligned with yours.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong><u>III. Financial Performance &amp; Outlook</u></strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>2024 Results Highlighted by Top-Line Growth and Cost Discipline</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">In 2024, Cosmos Health delivered steady top-line growth while making significant progress in improving efficiency, including meaningful cost-cutting measures.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Revenues increased</strong> to $54.43 million, an approximately 2% gain over 2023, supported by expansion in branded products and distribution.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Operating expenses decreased</strong> by approximately 24% year over year, with general and administrative costs down 40% and sales and marketing down 71%.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">These efforts reflect our disciplined approach to building a leaner, more scalable company. Despite these improvements, adjusted EBITDA was ($3.73 million), compared to a small gain in 2023, primarily due to increased investments in our facilities and research and development. Net loss widened to ($4.74 million); however, our balance sheet remained solid, with total assets of $54.31 million and equity of $24.53 million.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">These results laid the groundwork for the stronger performance we are seeing in 2025, reinforcing our confidence that the strategic investments made in 2024 are already beginning to yield results.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>2025 Momentum</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">In the opinion of the Company, our momentum has accelerated in 2025, reflecting the benefits of our strategic investments and the strength of our branded product portfolio.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Key highlights from the first half of 2025 include:</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Revenue Growth:</strong> $28.46 million in H1 2025, an increase of 11.7% compared to $25.49 million in H1 2024, driven by stronger demand and the expanding contribution of higher-margin branded products.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Margin Expansion:</strong> Gross profit rose to $3.21 million in H1 2025, up 53% year over year, underscoring the success of our strategic focus on nutraceuticals and contract manufacturing.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Operational Leverage:</strong> Efficiency gains at Cana Laboratories and CosmoFarm enhanced scalability, enabling us to capture growth while steadily improving profitability.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">As various key metrics, including EPS, continue to show improvement, this brings us one step closer to our strategic goal of delivering consistent positive operating cash flow.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Balance Sheet Strength</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Our balance sheet continued to strengthen in 2025, supporting growth while maintaining financial discipline. The increase in assets and equity highlights an improved financial position, giving Cosmos Health greater flexibility to execute its strategy with confidence.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Key financial metrics as of June 30, 2025, include:</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Total Assets:</strong> $61.84 million, up 13.9% from $54.31 million at year-end 2024.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Stockholders&#8217; Equity:</strong> $26.23 million, compared to $24.53 million at year-end 2024, reflecting an improved position.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Liabilities:</strong> $35.60 million, primarily from financing arrangements to support growth.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Liabilities-to-Assets Ratio:</strong> ~57.6%, maintaining a prudent capital structure.</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Beyond these figures, our valuable,<strong> wholly owned real estate assets</strong> - Cana Laboratories and CosmoFarm&#8217;s logistics center - serve not only as operational pillars but also as strategic financial resources. The &#8364;2.2 million bond loan facility, bearing interest of 2.95% plus the applicable 6-month Euribor, secured earlier this year against our CosmoFarm&#8217;s distribution center, illustrates how we can unlock financing flexibility on attractive terms.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Guidance to 2027</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Looking ahead, Cosmos Health is targeting continued growth and profitability, driven by <strong>disciplined execution</strong> and an accelerating shift toward <strong>higher-margin segments</strong>. For 2025, our sales to date are tracking close to our published guidance, and we remain confident in our trajectory toward 2026. These goals underscore both the scalability of our platform and the momentum we are building across branded products, advanced manufacturing, and logistics.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Key financial objectives by 2027 include:</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Revenue:</strong> Approximately $155.8 million.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Adjusted EBITDA:</strong> Expected to reach $29.4 million.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Positive Operating Cash Flow:</strong> A central near-term milestone, marking a turning point in Cosmos Health&#8217;s financial evolution.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">This trajectory will be driven by:</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Scaling our branded product portfolio</strong>, particularly Sky Premium Life&#174; and proprietary pharmaceuticals, which command higher margins.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Expanding utilization at Cana Laboratories and U.S. facilities</strong>, unlocking the full potential of our upgraded manufacturing capacity.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Enhancing CosmoFarm&#8217;s efficiency and reach</strong>, leveraging its role as a distribution hub serving over 1,500 pharmacies.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Maintaining strict financial discipline</strong>, with continued focus on cost controls and operating leverage.</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">With margins already improving and our business mix shifting toward higher-value categories, Cosmos Health is confident in its ability to achieve these targets and position the Company for sustained profitability. Reaching these milestones is expected to unlock substantial shareholder value, supported by internally generated cash flow that will enable us to reinvest in the business, pursue strategic acquisitions, and reward shareholders.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><u><strong>IV. Strategy &amp; Roadmap</strong></u></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Six Pillars of Growth</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Our roadmap is structured around six interconnected pillars, each representing a current priority as well as a long-term driver of value creation:</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Profitability and Cash Flow:</strong> Achieving and sustaining positive operating cash flow through disciplined cost management and scaling of high-margin businesses.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Innovation and Intellectual Property:</strong> Expanding our R&amp;D pipeline and advancing CCX0722 and oncology candidates, supported by Cloudscreen&#8217;s AI-driven discovery engine.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Manufacturing Scale:</strong> Leveraging dual GMP-certified hubs in Europe and the U.S. to provide global reach, flexibility, and resilience.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Market Development:</strong> Expanding Sky Premium Life&#174; and other brands across Europe, the Middle East, North America, and Asia.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Digital Assets and Tokenization:</strong> Building one of the largest digital treasuries in healthcare while piloting blockchain-enabled initiatives to enhance efficiency and transparency.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Acquisitions and Partnerships:</strong> Pursuing disciplined acquisitions and alliances to broaden distribution, technology, and branded products.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Strategic Outlook</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">As we look toward the rest of 2025 and beyond, Cosmos Health stands at an inflection point. Our strategy builds on three reinforcing pillars: <strong>Healthcare Innovation, Global Expansion, and Financial Strength</strong>.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Healthcare Innovation &amp; R&amp;D Leadership</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Innovation remains central to our growth story. Cloudscreen, our AI-enabled drug repurposing platform, is evolving into a next-generation engine capable of screening billions of compounds across multiple therapeutic areas. The launch of Cloudscreen 2.0 will enhance both internal discovery and opportunities for collaborations, licensing, and joint ventures.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; CCX0722, our proprietary obesity treatment, remains on track for a 2026 launch.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; We continue to expand our oncology and CNS portfolios through new discoveries and licensing.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; To unlock further value, we are evaluating strategic options such as a potential spin-off of our R&amp;D division, which could thrive independently while enabling Cosmos to sharpen its focus on scaling commercial platforms.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Global Expansion &amp; Market Penetration</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Cosmos is expanding rapidly across both geographies and business lines. Sky Premium Life&#174; continues to scale globally, with strong traction in Europe, the Middle East, and North America. Strategic investments in brand recognition, digital marketing, and e-commerce are designed to accelerate this momentum.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; Cana Laboratories is positioned as a global GMP-certified hub for contract manufacturing, with upgraded capacity already attracting multinational clients.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; Our active M&amp;A pipeline focuses on branded nutraceuticals, pharmaceutical assets, distribution companies, and digital health platforms, all evaluated with strict discipline to ensure strategic alignment and long-term value creation.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Financial Strength &amp; Shareholder Value Creation</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">We remain committed to maintaining financial strength and resilience.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; Our digital treasury strategy diversifies the balance sheet and positions Cosmos squarely at the intersection of healthcare and decentralized finance, providing growth optionality and protection against volatility.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; Operational efficiency is a central focus, reducing reliance on lower-margin segments while scaling higher-value proprietary products.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; Strong governance, transparency, and shareholder alignment remain priorities. Significant insider ownership and disciplined financing initiatives underscore our long-term commitment.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Sustainability Commitment</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Equally important is how we achieve these goals. Cosmos Health is committed to balancing growth with responsibility, guided by principles of sustainability and social impact. This commitment is reflected in areas such as:</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Natural product focus:</strong> Nutraceutical lines emphasizing clean, natural formulations inspired by the Mediterranean diet.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Responsible treasury strategy:</strong> A digital treasury approach that balances innovation with prudent risk management.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Patient access and well-being:</strong> A commitment to improving lives by making quality supplements and medicines more widely available, supporting healthier lifestyles and long-term wellness.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0.5in">&#9679;&nbsp;&nbsp;&nbsp;&nbsp; <strong>R&amp;D leadership:</strong> Advancing treatments for major global health challenges such as diabetes and cancer, leveraging AI-enabled discovery platforms and strategic collaborations to deliver innovation with meaningful human impact.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Together, these priorities reflect Cosmos Health&#8217;s dual mandate: to deliver enduring financial value for shareholders while advancing healthcare access and innovation for society.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>Closing Message</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">As we reflect on our recent milestones, we believe that Cosmos Health has entered a new era of growth, resilience, and innovation. With strengthened operations, a powerful treasury strategy, expanded manufacturing on both sides of the Atlantic, growing global brands, and a pipeline of AI-driven discoveries, we are building a company designed not just to compete, but to lead the future of healthcare. With your trust and support, I am confident that the momentum we are building today will translate into lasting value and enduring success in the years to come.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Sincerely,</p> <p style="margin:0px">Greg Siokas</p> <p style="margin:0px">CEO</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"><strong>About Cosmos Health Inc.</strong></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life&#174;, Mediterranation&#174;, bio-bebe&#174;, C-Sept&#174; and C-Scrub&#174;. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&amp;D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&amp;D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Forward-Looking Statements</strong></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;projects,&#8221; &#8220;estimates,&#8221; &#8220;plans,&#8221; and similar expressions, or future or conditional verbs such as &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;may,&#8221; and &#8220;could,&#8221; generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company&#8217;s control, including, but not limited to: the Company&#8217;s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company&#8217;s business, operations, and the economy in general; and the Company&#8217;s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company&#8217;s filings with the SEC, which are available at the SEC&#8217;s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Investor Relations Contact:</strong></p> <p style="MARGIN: 0px; text-align:justify;">BDG Communications</p> <p style="MARGIN: 0px; text-align:justify;">cosm@bdgcommunications.com</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid;"> <p style="text-align:center;margin:0px">11</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cosm-20250929.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 09/28/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-types="http://fasb.org/us-types/2025" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:cyd="http://xbrl.sec.gov/cyd-af-sub/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025" xmlns:cosm="http://cosm.com/20250929" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cosm.com/20250929">
 <annotation>
  <appinfo>
   <link:roleType roleURI="http://cosm.com/role/Cover" id="Cover">
    <link:definition>000001 - Document - Cover</link:definition>
    <link:usedOn>link:presentationLink</link:usedOn>
    <link:usedOn>link:calculationLink</link:usedOn>
    <link:usedOn>link:definitionLink</link:usedOn>
   </link:roleType>
   <link:linkbaseRef xlink:type="simple" xlink:href="cosm-20250929_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="cosm-20250929_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="cosm-20250929_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="cosm-20250929_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
  </appinfo>
 </annotation>
 <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
 <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
 <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
 <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
 <import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd" />
 <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
 <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
 <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
 <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
 <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
 <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cosm-20250929_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 09/28/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address Country</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre Commencement Issuer Tender Offer</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>cosm-20250929_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 09/28/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef  roleURI="http://cosm.com/role/Cover" xlink:href="cosm-20250929.xsd#Cover" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>cosm-20250929_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 09/28/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cosm.com/role/Cover" xlink:href="cosm-20250929.xsd#Cover" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>cosm-20250929_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 09/28/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef  roleURI="http://cosm.com/role/Cover" xlink:href="cosm-20250929.xsd#Cover" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 29, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COSMOS HEALTH INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001474167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 29,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-54436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-0611758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">5 Agiou Georgiou<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Pilea<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Thessaloniki<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">55438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">865-0026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">COSM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">GR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="cosm_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cosm-20250929.xsd</File>
    <File>cosm-20250929_cal.xml</File>
    <File>cosm-20250929_def.xml</File>
    <File>cosm-20250929_lab.xml</File>
    <File>cosm-20250929_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="cosm_8k.htm">cosm_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cosm_8k.htm": {
   "nsprefix": "cosm",
   "nsuri": "http://cosm.com/20250929",
   "dts": {
    "schema": {
     "local": [
      "cosm-20250929.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cosm-20250929_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cosm-20250929_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cosm-20250929_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cosm-20250929_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "cosm_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://cosm.com/role/Cover",
     "longName": "000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-09-29to2025-09-29",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-09-29to2025-09-29",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 2",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001477932-25-007111-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001477932-25-007111-xbrl.zip
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MBHUR2ASK575Z8B:/U#\!IJ=P\H]QU_\#4$L#!!0    ( &)//5M,3PT B00
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MW-67IIAQB=0/<HA*KM+;9=<*)3CC%A>L)VI!<UJR_!;I_.Z+A*C;REU=%.Y
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M!7'Z6NVNB7CN?4!A68$ED[0R%I'UM9-*Y>RP9G'.@GBF,+7T5$F8.IYV$X%
M5$K56%27CJ7A:;2CX@EI7MV04KF0@XK+Z8I#)H[6RO0!^+@\VG>%KK:0^!Z
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ME/0];5,O\K@EI[N%E2A6^;Q4E4",M#QWZ3$"G3Z<75WV(+;!Q7@_1)V38LM
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M$>SN]"C<H=""&KFZ#8Z>:\H,_3:0(CG;;AW[H_V='<]D<]1-=W''8&/B>:?
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MT+<EN?P\*L?+5_\74$L! A0#%     @ 8D\]6W&VOR!(!   Q!,  !$
M         ( !     &-O<VTM,C R-3 Y,CDN>'-D4$L! A0#%     @ 8D\]
M6P-=1GK: 0  BP,  !4              ( !=P0  &-O<VTM,C R-3 Y,CE?
M8V%L+GAM;%!+ 0(4 Q0    ( &)//5N!-SBAD0(  $0(   5
M  "  80&  !C;W-M+3(P,C4P.3(Y7V1E9BYX;6Q02P$"% ,4    " !B3SU;
MQDQ^#A4&  !Q.0  %0              @ %("0  8V]S;2TR,#(U,#DR.5]L
M86(N>&UL4$L! A0#%     @ 8D\]6TQ/#0")!   7"0  !4
M ( !D \  &-O<VTM,C R-3 Y,CE?<')E+GAM;%!+ 0(4 Q0    ( &)//5N=
M&L9=#Q(  )]K   +              "  4P4  !C;W-M7SAK+FAT;5!+ 0(4
M Q0    ( &)//5LTSWV)+S,  '[1   .              "  80F  !C;W-M
@7V5X.3DQ+FAT;5!+!08     !P ' , !  #?60     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>cosm_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cosm-20250929.xsd" xlink:type="simple"/>
    <context id="From2025-09-29to2025-09-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <startDate>2025-09-29</startDate>
            <endDate>2025-09-29</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2025-09-29to2025-09-29" id="ixv-314">0001474167</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2025-09-29to2025-09-29" id="ixv-315">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2025-09-29to2025-09-29" id="ixv-335">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2025-09-29to2025-09-29" id="ixv-336">2025-09-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2025-09-29to2025-09-29" id="ixv-337">COSMOS HEALTH INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-09-29to2025-09-29" id="ixv-338">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2025-09-29to2025-09-29" id="ixv-339">000-54436</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-09-29to2025-09-29" id="ixv-340">27-0611758</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-09-29to2025-09-29" id="ixv-341">5 Agiou Georgiou</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-09-29to2025-09-29" id="ixv-342">Pilea</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-09-29to2025-09-29" id="ixv-343">Thessaloniki</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="From2025-09-29to2025-09-29" id="ixv-344">GR</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2025-09-29to2025-09-29" id="ixv-345">55438</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-09-29to2025-09-29" id="ixv-346">312</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-09-29to2025-09-29" id="ixv-347">865-0026</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2025-09-29to2025-09-29" id="ixv-348">Common Stock, $.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-09-29to2025-09-29" id="ixv-349">COSM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-09-29to2025-09-29" id="ixv-350">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="From2025-09-29to2025-09-29" id="ixv-351">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2025-09-29to2025-09-29" id="ixv-352">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2025-09-29to2025-09-29" id="ixv-353">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2025-09-29to2025-09-29" id="ixv-354">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-09-29to2025-09-29" id="ixv-355">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
